Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents
- Autores
- Daniotti, Jose Luis; Lardone, Ricardo Dante; Vilcaes, Aldo Alejandro
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Glycolipids are complex molecules consisting of a ceramide lipid moiety linked to a glycan chain of variable length and structure. Among these are found the gangliosides, which are sialylated glycolipids ubiquitously distributed on the outer layer of vertebrate plasma membranes. Changes in the expression of certain species of gangliosides have been described to occur during cell proliferation, differentiation, and ontogenesis. However, the aberrant and elevated expression of gangliosides has been also observed in different types of cancer cells, thereby promoting tumor survival. Moreover, gangliosides are actively released from the membrane of tumor cells, having a strong impact on impairing anti-tumor immunity. Beyond the undesirable effects of gangliosides in cancer cells, a substantial number of cancer immunotherapies have been developed in recent years that have used gangliosides as the main target. This has resulted in successful immune cell- or antibody-responses against glycolipids, with promising results having been obtained in clinical trials. In this review, we provide a general overview on the metabolism of glycolipids, both in normal and tumor cells, as well as examining glycolipid-mediated immune modulation and the main successes achieved in immunotherapies using gangliosides as molecular targets.
Fil: Daniotti, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Lardone, Ricardo Dante. The John Wayne Cancer Institute; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vilcaes, Aldo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina - Materia
-
ANTIBODIES
CANCER
GANGLIOSIDES
GLYCOLIPIDS
IMMUNOTHERAPY
IMMUNOTOXIN - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/51890
Ver los metadatos del registro completo
id |
CONICETDig_7db91b72cd5a0cc9c116ea47da9e976c |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/51890 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsDaniotti, Jose LuisLardone, Ricardo DanteVilcaes, Aldo AlejandroANTIBODIESCANCERGANGLIOSIDESGLYCOLIPIDSIMMUNOTHERAPYIMMUNOTOXINhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Glycolipids are complex molecules consisting of a ceramide lipid moiety linked to a glycan chain of variable length and structure. Among these are found the gangliosides, which are sialylated glycolipids ubiquitously distributed on the outer layer of vertebrate plasma membranes. Changes in the expression of certain species of gangliosides have been described to occur during cell proliferation, differentiation, and ontogenesis. However, the aberrant and elevated expression of gangliosides has been also observed in different types of cancer cells, thereby promoting tumor survival. Moreover, gangliosides are actively released from the membrane of tumor cells, having a strong impact on impairing anti-tumor immunity. Beyond the undesirable effects of gangliosides in cancer cells, a substantial number of cancer immunotherapies have been developed in recent years that have used gangliosides as the main target. This has resulted in successful immune cell- or antibody-responses against glycolipids, with promising results having been obtained in clinical trials. In this review, we provide a general overview on the metabolism of glycolipids, both in normal and tumor cells, as well as examining glycolipid-mediated immune modulation and the main successes achieved in immunotherapies using gangliosides as molecular targets.Fil: Daniotti, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; ArgentinaFil: Lardone, Ricardo Dante. The John Wayne Cancer Institute; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Vilcaes, Aldo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; ArgentinaFrontiers Research Foundation2016-01-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/51890Daniotti, Jose Luis; Lardone, Ricardo Dante; Vilcaes, Aldo Alejandro; Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents; Frontiers Research Foundation; Frontiers in Oncology; 5; 7-1-2016; 300-3002234-943XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2015.00300info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fonc.2015.00300/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:47:57Zoai:ri.conicet.gov.ar:11336/51890instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:47:58.03CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
title |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
spellingShingle |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents Daniotti, Jose Luis ANTIBODIES CANCER GANGLIOSIDES GLYCOLIPIDS IMMUNOTHERAPY IMMUNOTOXIN |
title_short |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
title_full |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
title_fullStr |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
title_full_unstemmed |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
title_sort |
Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents |
dc.creator.none.fl_str_mv |
Daniotti, Jose Luis Lardone, Ricardo Dante Vilcaes, Aldo Alejandro |
author |
Daniotti, Jose Luis |
author_facet |
Daniotti, Jose Luis Lardone, Ricardo Dante Vilcaes, Aldo Alejandro |
author_role |
author |
author2 |
Lardone, Ricardo Dante Vilcaes, Aldo Alejandro |
author2_role |
author author |
dc.subject.none.fl_str_mv |
ANTIBODIES CANCER GANGLIOSIDES GLYCOLIPIDS IMMUNOTHERAPY IMMUNOTOXIN |
topic |
ANTIBODIES CANCER GANGLIOSIDES GLYCOLIPIDS IMMUNOTHERAPY IMMUNOTOXIN |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Glycolipids are complex molecules consisting of a ceramide lipid moiety linked to a glycan chain of variable length and structure. Among these are found the gangliosides, which are sialylated glycolipids ubiquitously distributed on the outer layer of vertebrate plasma membranes. Changes in the expression of certain species of gangliosides have been described to occur during cell proliferation, differentiation, and ontogenesis. However, the aberrant and elevated expression of gangliosides has been also observed in different types of cancer cells, thereby promoting tumor survival. Moreover, gangliosides are actively released from the membrane of tumor cells, having a strong impact on impairing anti-tumor immunity. Beyond the undesirable effects of gangliosides in cancer cells, a substantial number of cancer immunotherapies have been developed in recent years that have used gangliosides as the main target. This has resulted in successful immune cell- or antibody-responses against glycolipids, with promising results having been obtained in clinical trials. In this review, we provide a general overview on the metabolism of glycolipids, both in normal and tumor cells, as well as examining glycolipid-mediated immune modulation and the main successes achieved in immunotherapies using gangliosides as molecular targets. Fil: Daniotti, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina Fil: Lardone, Ricardo Dante. The John Wayne Cancer Institute; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Vilcaes, Aldo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina |
description |
Glycolipids are complex molecules consisting of a ceramide lipid moiety linked to a glycan chain of variable length and structure. Among these are found the gangliosides, which are sialylated glycolipids ubiquitously distributed on the outer layer of vertebrate plasma membranes. Changes in the expression of certain species of gangliosides have been described to occur during cell proliferation, differentiation, and ontogenesis. However, the aberrant and elevated expression of gangliosides has been also observed in different types of cancer cells, thereby promoting tumor survival. Moreover, gangliosides are actively released from the membrane of tumor cells, having a strong impact on impairing anti-tumor immunity. Beyond the undesirable effects of gangliosides in cancer cells, a substantial number of cancer immunotherapies have been developed in recent years that have used gangliosides as the main target. This has resulted in successful immune cell- or antibody-responses against glycolipids, with promising results having been obtained in clinical trials. In this review, we provide a general overview on the metabolism of glycolipids, both in normal and tumor cells, as well as examining glycolipid-mediated immune modulation and the main successes achieved in immunotherapies using gangliosides as molecular targets. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-01-07 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/51890 Daniotti, Jose Luis; Lardone, Ricardo Dante; Vilcaes, Aldo Alejandro; Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents; Frontiers Research Foundation; Frontiers in Oncology; 5; 7-1-2016; 300-300 2234-943X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/51890 |
identifier_str_mv |
Daniotti, Jose Luis; Lardone, Ricardo Dante; Vilcaes, Aldo Alejandro; Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents; Frontiers Research Foundation; Frontiers in Oncology; 5; 7-1-2016; 300-300 2234-943X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2015.00300 info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fonc.2015.00300/full |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Research Foundation |
publisher.none.fl_str_mv |
Frontiers Research Foundation |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842268893849059328 |
score |
13.13397 |